Prevalence of emerging treatment-induced mutations in metastatic ER-positive breast cancer.

Trial Identifier:	D3612L00003
Sponsor:	AstraZeneca
Start Date:	October 2024
Primary Completion Date:	December 2024
Study Completion Date:	December 2024
Condition:	Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Brazil, São Paulo	São Paulo, Brazil, 04513-020

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.